Skip to main content

Table 3 Relationship between background, clinical, laboratory predictors and all-cause mortality

From: Decline in eGFR and mortality among type II diabetic patients: a 3-year prospective cohort study from Palestine

Variables

All-cause mortality

 

Multivariate Results

Yes (n = 44)

No (n = 267)

   

Frequency

Frequency

P-value

Adjusted P-value

Adjusted OR (CI 95%)

Age at baseline(Mean ± SD)

64.4 ± 8.7

60.4 ± 10.3

0.014

0.831

1.01 (0.95–1.1)

Gender

     

 Male

29 (19.1%)

123 (80.9%)

0.015

0.701

0.79 (0.24–2.6)

 Female*

15 (9.4%)

144 (90.6%)

   

BMI at baseline

(Mean ± SD)

32.3 ± 6

32.9 ± 5.7

0.522

  

Smoker

     

 Yes

15 (15.6%)

81 (84.4%)

0.478

0.987

0.99 (0.3–3.2)

 No*

26 (12.6%)

180 (87.4%)

   

Hypertension

     

 Yes

37 (15.4%)

204 (84.6%)

0.149

0.740

0.75 (0.14–4.1)

 No*

5 (8.2%)

56 (91.8%)

   

HTN duration at baseline(Mean ± SD)

9.8 ± 8

8.7 ± 7.6

0.411

 

DM duration at baseline

(Mean ± SD)

13.6 ± 9.4

12.3 ± 8

0.331

  

eGFR at baseline

(Mean ± SD)

55.7 ± 26.4

76.6 ± 22.2

< 0.001

 

IRF at baseline (eGFR < 60)

     

 Yes

27 (32.1%)

57 (67.9%)

 

0.002

5.5 (1.8–16.8)

 No*

17 (7.5%)

210 (92.5%)

< 0.001

  

GFR decline

     

 Yes

18 (16.7%)

90 (83.3%)

< 0.001

0.001

10.8 (2.8–41.6)

 No*

3 (1.7%)

177 (98.3%)

   

HbA1C at baseline

(Mean ± SD)

8.1 ± 1.8

8.5 ± 2.1

0.215

 

HDL cholesterol at baseline(Mean ± SD)

47.9 ± 12.2

47.2 ± 14.2

0.857

 

LDL cholesterol at baseline(Mean ± SD)

92.7 ± 35.5

87.9 ± 29.3

0.535

 
  1. *Reference group;IRF: Impaired renal function, OR: Odds ratio, CI: Confidence interval